Predictive Oncology Inc (POAI)
Official siteHEALTH INFORMATION SERVICES
Last updated: Nov 13, 2026 at 4:00 PM ET
Predictive Oncology Inc (POAI) Financials: Revenue, Profit and Cash Flow
Predictive Oncology reported revenue of $1.62M for the fiscal year ended Dec 31, 2024, down 0.2% from the year before. That year, net income was -$12.20M with a net margin of -751.4%, operating cash flow was -$11.96M and free cash flow was -$11.97M. The quarter ended Sep 30, 2025 had revenue of $3.62K.
Revenue and Margins
Over the 9 years to Dec 2024, revenue grew from $654.35K, a compound annual rate of 10.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $1.62M | -0.2% | 49.1% | -673.7% | -751.4% |
| Dec 2023 | $1.63M | +8.1% | 62.6% | -744.5% | -859.1% |
| Dec 2022 | $1.51M | +6.0% | 66.4% | -1729.3% | -1709.6% |
| Dec 2021 | $1.42M | +13.4% | 65.7% | -1437.9% | -1383.6% |
| Dec 2020 | $1.25M | -11.3% | 64.3% | -996.9% | -2067.0% |
| Dec 2019 | $1.41M | 0.0% | 62.3% | -975.8% | -1373.7% |
| Dec 2018 | $1.41M | +115.6% | 70.5% | -556.9% | -714.5% |
| Dec 2017 | $654.84K | +43.4% | 77.4% | -1183.0% | -1183.0% |
| Dec 2016 | $456.50K | -30.2% | 60.2% | -1429.6% | -1429.6% |
| Dec 2015 | $654.35K | N/A | 53.5% | -672.4% | -732.1% |
Income Statement
In the fiscal year ended Dec 2024, the net loss narrowed from the year before.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.62M | $1.63M | $1.51M | $1.42M | $1.25M | $1.41M | $1.41M | $654.84K | $456.50K | $654.35K |
| Cost of revenue | $826.14K | $609.21K | $505.11K | $487.02K | $447.19K | $531.81K | $415.76K | $148.04K | $181.62K | $303.98K |
| Gross profit | $797.68K | $1.02M | $1.00M | $933.66K | $805.08K | $879.75K | $995.89K | $506.79K | $274.88K | $350.37K |
| Research and development | $25.99K | $122.31K | $320.32K | $315.85K | $2.35M | $2.96M | $1.86M | $289.00K | $406.00K | $261.00K |
| Operating income | -$10.94M | -$12.12M | -$26.03M | -$20.43M | -$12.48M | -$13.77M | -$7.86M | -$7.75M | -$6.53M | -$4.40M |
| Net income | -$12.20M | -$13.98M | -$25.74M | -$19.66M | -$25.88M | -$19.39M | -$10.09M | -$7.75M | -$6.53M | -$4.79M |
| EBITDA | -$10.24M | N/A | -$13.95M | -$12.13M | -$11.46M | -$12.41M | -$7.71M | -$5.98M | -$6.44M | -$4.32M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.62K | $2.68K | $110.31K | $611.59K | $345.69K | $278.72K | $419.65K | $335.03K | $676.63K | $490.11K | $239.90K | $363.47K |
| Gross profit | -$4.74K | -$185.79K | $65.19K | $320.96K | $148.77K | $125.75K | $69.67K | -$71.26K | $578.76K | $330.35K | $119.76K | $210.03K |
| Operating income | -$77.65M | -$2.66M | -$2.29M | -$2.12M | -$2.31M | -$3.19M | -$4.24M | -$3.51M | -$2.74M | -$3.96M | -$3.46M | -$4.43M |
| Net income | N/A | -$2.07M | -$2.44M | -$2.17M | -$3.09M | -$3.18M | -$4.22M | -$3.48M | -$3.16M | -$3.92M | -$4.26M | -$22.26M |
Balance Sheet
As of Dec 2024, cash and equivalents of $734.67K were 14.8% of total assets of $4.97M, against total liabilities of $5.18M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.97M | $14.42M | $25.73M | $43.77M | $13.06M | $22.38M | $3.71M | $3.62M | $2.81M | $5.63M |
| Current assets | $2.23M | $10.08M | $23.36M | $29.46M | $1.51M | $798.26K | $1.45M | $2.37M | $2.61M | $5.40M |
| Cash and equivalents | $734.67K | $8.73M | $22.07M | $28.20M | $678.33K | $150.83K | $162.15K | $766.19K | $1.76M | $4.86M |
| Total liabilities | $5.18M | $6.15M | $3.97M | $3.51M | $10.42M | $11.14M | $3.66M | $932.34K | $1.88M | $1.52M |
| Shareholder equity | -$202.61K | $8.27M | $21.77M | $40.27M | $2.64M | $11.23M | $53.47K | $2.69M | $923.68K | $4.11M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.14M | $3.44M | $5.87M | $4.97M | $7.50M | $10.59M | $10.60M | $14.42M | $18.17M | $20.97M | $25.06M | $25.73M |
| Total liabilities | $80.57M | $5.09M | $6.01M | $5.18M | $5.53M | $6.49M | $6.55M | $6.15M | $6.52M | $6.26M | $6.51M | $3.97M |
| Cash and equivalents | $181.67K | $506.08K | $3.09M | $734.67K | $3.08M | $5.33M | $5.20M | $8.73M | $11.92M | $14.76M | $18.60M | $22.07M |
| Shareholder equity | -$77.43M | -$1.65M | -$145.80K | -$202.61K | $1.97M | $4.09M | $4.05M | $8.27M | $11.65M | $14.71M | $18.55M | $21.77M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.96M | -$13.19M | -$12.37M | -$12.21M | -$12.26M | -$8.73M | -$5.29M | -$4.46M | -$4.38M | -$7.49M |
| Capital expenditures | $9.51K | $21.53K | $475.70K | $962.32K | $360.78K | $26.61K | $232.00K | $55.27K | $44.75K | $60.56K |
| Free cash flow | -$11.97M | -$13.21M | -$12.85M | -$13.17M | -$12.62M | -$8.76M | -$5.52M | -$4.52M | -$4.43M | -$7.55M |
| Dividends paid | N/A | $794 | N/A | $4.51M | $2.96B | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $22.49K | -$302.37K | -$475.70K | -$10.61M | -$167.46K | -$599.09K | -$1.11M | -$1.65M | -$422.86K | -$60.56K |
| Financing cash flow | $3.94M | $148.90K | $6.72M | $50.34M | $12.95M | $9.32M | $5.79M | $5.11M | $1.71M | $12.39M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.65M | -$3.32M | -$756.35K | -$3.04M | -$2.28M | -$3.22M | -$3.42M | -$3.08M | -$3.10M | -$3.57M | -$3.43M | -$3.23M |
| Capital expenditures | $3 | $0 | $0 | $0 | $3 | $6.48K | $3.03K | $7.29K | $3.92K | $259.10K | $46.64K | $63.60K |
| Free cash flow | -$1.65M | -$3.32M | -$756.35K | -$3.04M | -$2.28M | -$3.22M | -$3.42M | -$3.09M | -$3.11M | -$3.83M | -$3.47M | -$3.30M |
Frequently Asked Questions About POAI
What is Predictive Oncology's annual revenue?
Predictive Oncology reported revenue of $1.62M for the fiscal year ended Dec 31, 2024.
How fast is Predictive Oncology's revenue growing?
Revenue was down 0.2% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 4.6%.
Is Predictive Oncology profitable?
No. Predictive Oncology reported net income of -$12.20M for the fiscal year ended Dec 31, 2024, with a net margin of -751.4%.
How much free cash flow does POAI generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$11.96M minus capital expenditures of $9.51K produced free cash flow of -$11.97M.
How much debt does Predictive Oncology have?
The balance sheet dated Dec 31, 2024 reported cash and equivalents of $734.67K.
POAI pages: Overview, Financials